Alimera Sciences (ALIM) Receives “Buy” Rating from HC Wainwright

Alimera Sciences (NASDAQ:ALIM)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday. They currently have a $5.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 331.03% from the stock’s current price.

A number of other equities research analysts have also commented on the stock. Cowen reaffirmed a “buy” rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. Zacks Investment Research lowered shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Monday, November 27th. Finally, ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research note on Monday, November 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $3.38.

Alimera Sciences (ALIM) traded down $0.04 during trading hours on Monday, hitting $1.16. 323,202 shares of the stock were exchanged, compared to its average volume of 136,813. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84. Alimera Sciences has a 12 month low of $1.11 and a 12 month high of $1.72. The company has a market cap of $80.21, a price-to-earnings ratio of -3.74 and a beta of 2.15.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. equities analysts expect that Alimera Sciences will post -0.27 EPS for the current year.

In related news, CEO C. Daniel Myers sold 52,900 shares of the stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $65,067.00. Following the transaction, the chief executive officer now directly owns 154,411 shares of the company’s stock, valued at $189,925.53. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Philip Ashman sold 25,500 shares of the stock in a transaction on Friday, January 19th. The stock was sold at an average price of $1.20, for a total transaction of $30,600.00. Following the transaction, the senior vice president now directly owns 12,750 shares in the company, valued at $15,300. The disclosure for this sale can be found here. Over the last three months, insiders have sold 184,704 shares of company stock worth $224,432. 14.70% of the stock is owned by insiders.

An institutional investor recently raised its position in Alimera Sciences stock. Stonepine Capital Management LLC increased its stake in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 477,226 shares of the biopharmaceutical company’s stock after acquiring an additional 292,399 shares during the quarter. Alimera Sciences makes up about 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned approximately 0.69% of Alimera Sciences worth $644,000 as of its most recent filing with the Securities & Exchange Commission. 41.77% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.

Leave a Reply